Nicholas K Weber1, Lisa M Forman, James F Trotter. 1. Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, Aurora, CO 80045, USA. nicholas.weber@ucdenver.edu
Abstract
BACKGROUND: Hepatitis B (HBV) is an uncommon indication for liver transplantation in the US accounting for approximately 5% of cases. Recurrence prophylaxis is typically long-term hepatitis B immune-globulin (HBIg) and an oral anti-HBV agent. Because of high HBIg costs and improving efficacy of new oral agents, there is increasing interest in HBIg discontinuation. AIM: To describe results of a protocol at our center including HBV vaccination and HBIg discontinuation. METHODS: All patients received HBIg therapy and an oral anti-viral agent from the time of transplant. Patients transplanted for HBV with a stable post-operative clinical course underwent HBV vaccination and HBIg discontinuation. After HBIg discontinuation, patients were monitored for HBV recurrence for at least one year. Recurrence was defined as either viral (HBV-DNA 10(4) copies/ml on two consecutive occasions) or hepatitis (viral recurrence with elevated liver transaminases). RESULTS: Of 1182 recipients, 36 (3%) had HBV. Twenty-four were excluded from the protocol, and the remaining 12 patients underwent HBIg withdrawal. Median age at HBIg discontinuation was 56 (range, 36-70) years, median time from transplant to HBIg discontinuation was 62.8 (range, 27.5-128) months, and median time of follow-up after discontinuation was 27.4 (range, 13-69) months. Of the 12 patients vaccinated, no patients maintained HBSAb >or= 10 IU/l at last follow-up. There was no viral or hepatitis recurrence and no deaths or graft loss. CONCLUSIONS: HBIg discontinuation with maintenance oral anti-viral monotherapy is safe and effective for HBV liver transplant recipients. Vaccination is not effective in this population.
BACKGROUND:Hepatitis B (HBV) is an uncommon indication for liver transplantation in the US accounting for approximately 5% of cases. Recurrence prophylaxis is typically long-term hepatitis B immune-globulin (HBIg) and an oral anti-HBV agent. Because of high HBIg costs and improving efficacy of new oral agents, there is increasing interest in HBIg discontinuation. AIM: To describe results of a protocol at our center including HBV vaccination and HBIg discontinuation. METHODS: All patients received HBIg therapy and an oral anti-viral agent from the time of transplant. Patients transplanted for HBV with a stable post-operative clinical course underwent HBV vaccination and HBIg discontinuation. After HBIg discontinuation, patients were monitored for HBV recurrence for at least one year. Recurrence was defined as either viral (HBV-DNA 10(4) copies/ml on two consecutive occasions) or hepatitis (viral recurrence with elevated liver transaminases). RESULTS: Of 1182 recipients, 36 (3%) had HBV. Twenty-four were excluded from the protocol, and the remaining 12 patients underwent HBIg withdrawal. Median age at HBIg discontinuation was 56 (range, 36-70) years, median time from transplant to HBIg discontinuation was 62.8 (range, 27.5-128) months, and median time of follow-up after discontinuation was 27.4 (range, 13-69) months. Of the 12 patients vaccinated, no patients maintained HBSAb >or= 10 IU/l at last follow-up. There was no viral or hepatitis recurrence and no deaths or graft loss. CONCLUSIONS: HBIg discontinuation with maintenance oral anti-viral monotherapy is safe and effective for HBV liver transplant recipients. Vaccination is not effective in this population.
Authors: A Sánchez-Fueyo; A Rimola; L Grande; J Costa; A Mas; M Navasa; I Cirera; J M Sánchez-Tapias; J Rodés Journal: Hepatology Date: 2000-02 Impact factor: 17.425
Authors: Jens Rosenau; Nazanin Hooman; Kinan Rifai; Therese Solga; Hans L Tillmann; Edith Grzegowski; Björn Nashan; Juergen Klempnauer; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns Journal: Transpl Int Date: 2006-10 Impact factor: 3.782
Authors: N V Naoumov; A R Lopes; P Burra; L Caccamo; R M Iemmolo; R A de Man; M Bassendine; J G O'Grady; B C Portmann; G Anschuetz; C A Barrett; R Williams; M Atkins Journal: J Hepatol Date: 2001-06 Impact factor: 25.083
Authors: S H Han; J Ofman; C Holt; K King; G Kunder; P Chen; S Dawson; L Goldstein; H Yersiz; D G Farmer; R M Ghobrial; R W Busuttil; P Martin Journal: Liver Transpl Date: 2000-11 Impact factor: 5.799
Authors: María Buti; Antoni Mas; Martín Prieto; Fernando Casafont; Antonio González; Manuel Miras; Jose Ignacio Herrero; Rossendo Jardí; Eva Cruz de Castro; César García-Rey Journal: J Hepatol Date: 2003-06 Impact factor: 25.083
Authors: Peter W Angus; Scott J Patterson; Simone I Strasser; Geoffrey W McCaughan; Edward Gane Journal: Hepatology Date: 2008-11 Impact factor: 17.425
Authors: Miguel Jiménez-Pérez; Rocío González-Grande; José Mostazo Torres; Carolina González Arjona; Francisco Javier Rando-Muñoz Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742
Authors: Ramin Raul Ossami Saidy; Irina Sud; Franziska Eurich; Mustafa Aydin; Maximilian Paul Postel; Eva Maria Dobrindt; Johann Pratschke; Dennis Eurich Journal: Viruses Date: 2021-05-13 Impact factor: 5.048